[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrauterine-adhesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrauterine-adhesions":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,68,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100639961","to-evaluate-the-safety-and-effectiveness-of-intrauterine-adhesion-preventer-in-the-prevention-and-treatment-of-intrauterine-adhesions-a-prospective-multicenter-randomized-controlled-clinical-trial-100639961",false,"NCT07611474","To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients clinically diagnosed with intrauterine adhesions and with surgical indications (referring to those with fertility requirements or obstructed menstrual blood drainage) ② Women aged 20-40 years old; ③ Subjects voluntarily participated in the trial and signed informed consent.\n\nExclusion Criteria:\n\n* ① Patients with obviously abnormal uterine cavity shape after surgery; those who could not clearly separate the normal uterine cavity anatomical morphology (i.e. bilateral or unilateral fallopian tube openings were not visible); those with reproductive organ malformations and uterine cavities that were too large or too small; those with recent uterine perforation; those with cervical insufficiency.\n\n  * Those with a history of intrauterine adhesions and treatment;\n\n    * Those with endometrial tuberculosis or suspected endometrial tuberculosis;\n\n      * Those with adenomyosis or uterine fibroids\\>4cm;\n\n        * Those with a history of malignant tumors or suspected malignant tumors;\n\n          * Those with acute and chronic intrauterine infection and genital infection;\n\n            * Those with unexplained vaginal bleeding or suspected uterine malignant lesions;\n\n              * Those with severe anemia and abnormal coagulation function; those with a history of thrombosis; ⑨ Those in the acute stage of various diseases or severe systemic diseases;\n\n                * Those with severe mental illness and physical weakness who cannot tolerate this operation;\n\n                  ⑪ Those with severe heart, liver, and kidney function diseases;\n\n                  ⑫ Those with contraindications to anesthesia or surgery;\n\n                  ⑬ Those who have participated in clinical trials in the past three months.\n                  * Those who are considered unsuitable for inclusion by the researchers.","FEMALE","20 Years","40 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","To evaluate the effect of uterine stents in preventing intrauterine adhesions after intrauterine operation and whether they meet the safety requirements for clinical use. The trial adopted a prospective, multicenter, randomized controlled, non-inferiority clinical trial design. The target population of the trial was 200 women aged 20-40 years with intrauterine adhesions and surgical indications (referring to those with fertility requirements or menstrual blood drainage obstruction), who were randomly divided into an experimental group and a control group, with 100 cases in each group. The experimental group was the group with intrauterine stents placed in the uterine cavity after hysteroscopic intrauterine adhesion separation surgery, and the control group was the group with intrauterine rings + balloons + sodium hyaluronate gel placed in the uterine cavity. After 3 courses of artificial cycles, the patients were hospitalized for hysteroscopy review.",[26,27],"Intrauterine Adhesion","Intrauterine Adhesions","RECRUITING","2026-05-20",{"date":31,"type":32},"2026-05-28","ACTUAL",{"date":34,"type":32},"2021-01-01",{"date":36,"type":20},"2031-12-31",{"name":38,"class":39},"The Third Xiangya Hospital of Central South University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100634229","clinical-study-of-i-prf-intrauterine-perfusion-for-endometrial-regeneration-and-repair-in-moderate-to-severe-intrauterine-adhesions-100634229","NCT07536971","Clinical Study of i-PRF Intrauterine Perfusion for Endometrial Regeneration and Repair in Moderate to Severe Intrauterine Adhesions","A Randomized Controlled Clinical Study on the Effect of i-PRF Intrauterine Perfusion on Endometrial Regeneration and Repair in Patients With Moderate to Severe Intrauterine Adhesions","IPRF-IUA","Inclusion Criteria:\n\n* Female participants aged 20 to 40 years\n* Moderate to severe intrauterine adhesions caused by endometrial injury, defined according to the Chinese diagnostic and grading standard (CSGE score \\>=9)\n* Strong desire for fertility\n* Normal ovarian function\n* Planned to undergo hysteroscopic adhesiolysis with uterine cavity reconstruction\n* Willing to comply with follow-up requirements\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications to hysteroscopic uterine cavity reconstruction surgery\n* Use of aspirin or other antiplatelet nonsteroidal anti-inflammatory drugs within 10 days before or after surgery\n* Hematologic disorders, including platelet dysfunction, severe anemia, or blood-borne infection\n* Contraindications to postoperative estrogen or progestin treatment\n* Other uterine diseases, such as congenital uterine malformation, adenomyosis, or submucosal fibroids\n* Other causes of infertility, including endocrine abnormalities, polycystic ovary syndrome, diminished ovarian reserve, premature ovarian insufficiency, or premature ovarian failure\n* History of pelvic malignancy or pelvic radiotherapy\n* Severe hepatic or renal dysfunction\n* Contraindications to pregnancy\n* Male partner-related infertility factors, such as abnormal semen findings","18 Years",{"count":19,"type":20},[23],"Intrauterine adhesions (IUA) caused by endometrial basal layer injury can lead to reduced menstrual flow, infertility, recurrent pregnancy loss, and poor reproductive outcomes. Hysteroscopic adhesiolysis with uterine cavity reconstruction is the standard treatment, but women with moderate to severe IUA still have high rates of re-adhesion and unsatisfactory endometrial repair after surgery.\n\nInjectable platelet-rich fibrin (i-PRF) is an autologous blood-derived biologic material that can be prepared at the bedside. Compared with conventional platelet-rich plasma, i-PRF may provide a more sustained release of growth factors and form a fibrin scaffold after intrauterine administration, which may help protect the wound surface, support endometrial regeneration, improve blood perfusion, and reduce postoperative re-adhesion.\n\nThis prospective randomized controlled study will evaluate the efficacy and safety of intrauterine i-PRF perfusion in women with moderate to severe IUA after hysteroscopic adhesiolysis. Participants will be assigned to receive either i-PRF intrauterine perfusion or sodium hyaluronate intrauterine treatment after surgery. The study will compare postoperative uterine cavity recovery, endometrial thickness and blood flow, clinical pregnancy outcomes, and safety events. The goal is to determine whether i-PRF can improve endometrial regeneration and reproductive outcomes and provide evidence for an optimized postoperative treatment strategy for moderate to severe IUA.",[27],[27,55,56,57],"TCRA","Platelet-Rich Plasma","RCT","NOT_YET_RECRUITING","2026-04-12",{"date":61,"type":32},"2026-04-17",{"date":63,"type":20},"2026-05-01",{"date":65,"type":20},"2029-06-30",{"name":67,"class":39},"Beijing Obstetrics and Gynecology Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100606483","hbmsc-uterine-artery-infusion-for-severe-iua-related-infertility-100606483","NCT07176143","hBMSC Uterine Artery Infusion for Severe IUA-Related Infertility","Study on the Clinical Efficacy and Safety of Infusing Human Bone Marrow Mesenchymal Stem Cells Via Uterine Artery for the Treatment of Infertility Due to Severe Intrauterine Adhesions","Inclusion Criteria:\n\n1. Subjects fully comprehend the screening process and study objectives, demonstrate adequate understanding of and compliance with the trial protocol, and provide signed informed consent.\n2. Age between 20 and 38 years.\n3. Body mass index (BMI) 18-27 kg\u002Fm².\n4. Regular menstrual cycles (27-35 days) for ≥6 months.\n5. Normal ovarian reserve: Antral follicle count (AFC) ≥6; Follicle-stimulating hormone (FSH) 1-10 IU\u002FL on cycle days 2-4; Baseline sex hormones within normal laboratory ranges.\n6. Negative serology within 6 months for: HIV antibodies; Treponema pallidum antibodies (TPA); Hepatitis B surface antigen (HBsAg); Hepatitis C virus antibodies (HCV-Ab).\n7. ≥2 good-quality blastocysts (D5\u002FD6) according to Gardner grading criteria.\n8. Prior hysteroscopic diagnosis of severe intrauterine adhesions (IUA) treated with electroresection, with normal uterine cavity morphology confirmed by hysteroscopy within 3 months.\n9. History of canceled frozen embryo transfers due to persistently thin endometrium (\\\u003C6 mm) in HRT and\u002For natural cycles during the late proliferation phase.\n\nExclusion Criteria:\n\n1. Ovarian cysts ≥20 mm, submucosal\u002Fintramural uterine fibroids \\>30 mm, pituitary tumors, or malignancy in any organ.\n2. Clinically significant uterine (endometrial polyps, IUA, malformations, endometriosis) or adnexal (hydrosalpinx) abnormalities.\n3. Recurrent implantation failure (≥3 consecutive transfers with ≥6 good-quality embryos failing).\n4. Unexplained abnormal vaginal bleeding.\n5. Active pelvic inflammatory disease.\n6. Reproductive tract malformations incompatible with pregnancy.\n7. Abnormal cervical cytology (TCT) within 1 year before screening.\n8. Severe hepatic\u002Frenal impairment, cardiac disease, or hypertension.\n9. History of thrombophlebitis or thromboembolism.\n10. Platelet count \\\u003C100×10⁹\u002FL, hemoglobin \\\u003C100 g\u002FL, or hematologic disorders (e.g., idiopathic thrombocytopenic purpura).\n11. Clinically significant systemic diseases (e.g., diabetes, tuberculosis).\n12. History of recurrent miscarriage.\n13. Chromosomal abnormalities in either partner.\n14. Genetic disorders (per Maternal and Infant Health Care Law) contraindicating pregnancy in either partner.\n15. Exposure to teratogenic radiation, toxins, or medications in either partner.\n16. Participation in other drug\u002Fdevice trials within 3 months prior to enrollment.\n17. Any condition (comorbidity, surgery, medication, or abnormal lab results) deemed by investigators to affect trial outcomes.\n18. Inability or refusal to comply with protocol requirements (including scheduled visits and tests).","38 Years",{"count":77,"type":20},60,[23],"The goal of this clinical trial is to test a new approach: delivering human bone marrow mesenchymal stem cells (hBMSCs) via the uterine artery to treat infertility caused by severe intrauterine adhesions (IUA). This method may help stem cells better reach the deep layer of the endometrium, promote endometrial repair, and improve pregnancy chances.\n\nPrimary Objective: To assess whether stem cell therapy improves pregnancy success rates (clinical pregnancy rate after embryo transfer) in infertility patients with severe IUA undergoing IVF.\n\nSecondary Objectives:\n\n1. To evaluate the safety of stem cell therapy (e.g., side effects or complications).\n2. To explore how stem cells help repair the endometrium (e.g., by promoting endometrial growth or improving uterine conditions).\n\nBy tracking endometrial thickness, embryo implantation rate, clinical pregnancy rate, and other indicators, we will evaluate whether this new approach is safe and effective.\n\nTreatment Groups:\n\nControl group: Standard hormone replacement therapy (HRT) cycle medication only.\n\nStem cell therapy group: Standard HRT medication + hBMSC infusion via uterine artery.\n\nBoth groups will undergo embryo transfer, and clinical pregnancy rates will be compared.",[27],[82,83,84],"intrauterine adhesions","uterine artery perfusion","human bone marrow mesenchymal stem cells","2025-09-09",{"date":87,"type":32},"2025-09-16",{"date":89,"type":20},"2025-09-30",{"date":91,"type":20},"2028-12-30",{"name":93,"class":39},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100585006","phase-1-evaluating-mechanically-engineered-stem-cell-exosomes-for-treating-endometrial-injury-a-clinical-study-100585006","NCT06896747","Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study","Evaluation of the Therapeutic Effects of Mechanically Engineered Umbilical Cord-Derived Stem Cell Exosomes on Endometrial Injury: A Prospective, Non-Randomized, Parallel-Controlled Clinical Study","Inclusion Criteria:\n\n1. Females aged 20-40 years (inclusive of boundary values);\n2. Normal ovarian reserve function (criteria: AFC ≥ 7, AMH \\> 1.1 ng\u002FmL);\n3. History of transcervical resection of adhesions (TCRA);\n4. Received PRP treatment after TCRA;\n5. At least one embryo transfer (ET) cycle in which they underwent standard ovarian stimulation (fresh cycle) or standard hormone replacement therapy (FET cycle), with an endometrial thickness of \\\u003C7 mm;\n6. Planned to continue IVF\u002FICSI\u002FFET-assisted conception;\n7. Able to accept and adhere to treatment and follow-up and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with severe systemic diseases, surgical contraindications, or cycle contraindications;\n2. Patients with reproductive tract infections, genital tuberculosis, pelvic inflammatory disease, or malignant tumors of reproductive organs;\n3. Patients with systemic diseases that cause uterine bleeding;\n4. Patients allergic to any drugs, materials, or components used in this study;\n5. Patients at high risk for hormone-dependent tumors such as breast cancer or ovarian tumors;\n6. Patients with untreated submucosal fibroids of any size (FIGO 0\u002FI\u002FII), uterine fibroids ≥5 cm (FIGO III, IV, V, VI, VII), adenomyosis, unicornuate uterus, bicornuate uterus, or endometrial polyps;\n7. Patients with hydrosalpinx ≥3 cm or hydrosalpinx of any size with significant vaginal discharge;\n8. Patients with ovarian endometriotic cysts (chocolate cysts) ≥4 cm;\n9. Patients who participated in other clinical trials within 3 months before surgery or during the study period;\n10. Patients unable to tolerate anesthesia;\n11. Patients with genetic abnormalities;\n12. Other patients deemed unsuitable for participation in this study by the investigator.",{"count":102,"type":20},90,[104,105],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate if engineered mechanically umbilical cord-derived stem cell exosomes, or conventional umbilical cord -derived stem cell exosomes, can improve endometrial thickness in women with thin endometrium.\n\nThe main questions it aims to answer are:\n\nCan exosomes delivered via subendometrial injection improve endometrial thickness or clinical pregnancy rates compared to PRP (platelet-rich plasma)? Are there significant differences in endometrial thickness between the two treatment groups? Researchers will compare the intervention groups, which one group receives mechanical exosomes and the other receives conventional esosomes via subendometrial injection, to the control group, which receives PRP via the same methods, to see if exosomes provide superior therapeutic effects.\n\nParticipants will:\n\nReceive either mechanical exosomesor or conventional esosomes or PRP through subendometrial injection.\n\nBe monitored for changes in endometrial parameters.",[108,109,27],"Thin Endometrial Lining","Female Infertility","2025-03-19",{"date":112,"type":32},"2025-03-26",{"date":114,"type":32},"2025-02-21",{"date":116,"type":20},"2027-03-31",{"name":118,"class":39},"Tang-Du Hospital",2]